Infectious diseases like smallpox, plague, HIV AIDS, malaria and others have been ravaging the world since their discovery. In 2020, to combat the current COVID-19 pandemic the world saw the rapid development of emergency use early vaccines. However, the fight for COVID-19 is far from over and the search for long-term protection continues. Since the beginning of the pandemic, Tonix has been developing a pipeline of product candidates for COVID-19, including a COVID-19 vaccine based on Tonix’s smallpox vaccine candidate. Through both proprietary, in-house initiatives, as well as strategic collaborations, Tonix is working to develop new vaccines and therapeutics related to COVID-19 and other emerging infections that could become the next pandemic. Tonix’s pandemic preparedness efforts are targeted to put a stop to all such public health emergencies.
SARS-CoV-2 is an extremely contagious infection causing the disease COVID-19, that became a global pandemic in 2019 and proved catastrophic to the world. The death toll is upwards of 3 million globally, and while the infection and mortality rates have slowed, the struggle is ongoing. COVID-19 is characterized by fever, sore throat, acute shortness of breath, cough, and oxygen depreciation in the blood. Until the early vaccines came along, management of symptoms was the course of treatment. This disease continues to ravage countries across the world and overwhelm healthcare systems. With new strains of the virus emerging, clinical research must keep up to the pace and match the pace of the fast-changing virus. The early vaccines have been exceptional in controlling the spread; however, more vaccines need to be developed to combat this virus from all aspects of its evolution. Vaccines that not only cause an antibody reaction, but also elicits a T cell response would be the ones that offer a long-term protection.
As of June 1, 2022
Confirmed Cases Worldwide
Fully Vaccinated People
Long COVID or Post-Acute Sequelae of COVID-19 (PASC), is a condition that survivors of COVID-19 infection experience at varying degrees. It is a chronic disabling condition that is expected to result in a significant global health and economic burden.1 The symptoms include intense fatigue, fevers, sleep problems, pain, and cognitive issues (“brain fog”). Post infection, many patients experience one or many of the symptoms of Long COVID: some patients have initial symptoms that become prolonged; others manifest entirely new syndromes that impact more than one system or organ. According to a recent publication in the Journal of American Medical Association (JAMA), over 1 in 10 healthcare workers who had recovered from COVID-19 were still coping with at least one moderate to severe symptom eight months later.2 Several cohort studies have reported that persistence of symptoms following SARS-CoV-2 infection occurs in more than 30% of patients.3 There is currently no approved drug for the treatment of Long COVID.
1 Briggs, Andrew, and Anna Vassall. “Count the cost of disability caused by COVID-19.” (2021): 502-505.
2 Symptoms and functional impairment assessed 8 Months after mild COVID-19 among health care workers. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thålin C. JAMA. 2021 Apr 7.
3 Nalbandian, Ani, et al. “Post-acute COVID-19 syndrome.” Nature Medicine (2021): 1-15.
Smallpox is the result of an infection by the variola virus (VARV) that belongs to the genus Orthopoxvirus. This is an extremely progressive and contagious infection that led to death if not treated quickly. Symptoms included fever, nausea, muscle ache and extreme skin pustules or rash. Smallpox infection is caused by inhalation of the airborne variola virus. The last detected case of Smallpox was in 1977 and by 1980 the World Health Organization has deemed Smallpox eradicated. However, the threat of this infection being used as a bioweapon remains as contagion and mortality rates are extremely high, and hence, an effective vaccine is of utter importance.